Cargando…
BRAF非V600E突变型肺癌靶向治疗的策略探索
BACKGROUND AND OBJECTIVE: Dabrafenib+Trametinib/Dabrafenib targeted therapy has been approved for V-RAF murine sarcoma viral oncogene homolog B1 with amino acid substitution for valine at position 600 (BRAF V600E) in lung cancer patients, however, the targeted therapy strategy for lung cancer patien...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913290/ https://www.ncbi.nlm.nih.gov/pubmed/35224961 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.51 |